Literature DB >> 9451421

The management of crisis in sickle cell disease.

I Okpala1.   

Abstract

The symptoms and signs of sickle cell disease are exacerbated in times of crisis, characterized by tissue infarction or worsening anaemia. Prompt medical intervention is required in these distressing situations to provide relief and comfort to the patient. Effective analgesia is crucial in treating the painful crisis of sickle cell disease. The haemoglobinopathy may cause hyposthenuria with reduced ability to excrete the sodium load in normal saline. A 5% dextrose solution or 5% dextrose in 25% normal saline is therefore recommended for intravenous hydration. As the leading cause of morbidity and mortality in sickle cell disease, infections call for vigorous antibiotic therapy. Oxygen administration should be reserved for hypoxic patients, and blood transfusion given only when really indicated. Acute chest syndrome and cerebrovascular accidents are life-threatening complications of sickle cell disease whereas priapism can cause important long-term sequelae; all deserve urgent attention. In the long term, comprehensive care is cost-effective in reducing the frequency and adverse effects of sickle cell crisis.

Entities:  

Mesh:

Year:  1998        PMID: 9451421     DOI: 10.1111/j.1600-0609.1998.tb00989.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  7 in total

1.  American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain.

Authors:  Amanda M Brandow; C Patrick Carroll; Susan Creary; Ronisha Edwards-Elliott; Jeffrey Glassberg; Robert W Hurley; Abdullah Kutlar; Mohamed Seisa; Jennifer Stinson; John J Strouse; Fouza Yusuf; William Zempsky; Eddy Lang
Journal:  Blood Adv       Date:  2020-06-23

2.  Normal saline bolus use in pediatric emergency departments is associated with poorer pain control in children with sickle cell anemia and vaso-occlusive pain.

Authors:  Marcus A Carden; David C Brousseau; Fahd A Ahmad; Jonathan Bennett; Seema Bhatt; Amanda Bogie; Kathleen Brown; Theron Charles Casper; Laura L Chapman; Corrie E Chumpitazi; Daniel Cohen; Carlton Dampier; Angela M Ellison; Hartmut Grasemann; Robert W Hickey; Lewis L Hsu; Sara Leibovich; Elizabeth Powell; Rachel Richards; Syana Sarnaik; Debra L Weiner; Claudia R Morris
Journal:  Am J Hematol       Date:  2019-04-29       Impact factor: 10.047

3.  On artherogenic index of plasma in sickle cell anaemia patients.

Authors:  Akinsegun Abduljaleel Akinbami; Ebele Ifeyinwa Uche; Aishatu Maude Suleiman; Ann Abiola Ogbenna; Festus Olusola Olowoselu; Benjamin Augustine; Mulikat Adesola Badiru; Rafat Abiodun Bamiro; Omolara Risqat Kamson
Journal:  Pan Afr Med J       Date:  2019-03-25

4.  Haematological values in homozygous sickle cell disease in steady state and haemoglobin phenotypes AA controls in Lagos, Nigeria.

Authors:  Akinsegun Akinbami; Adedoyin Dosunmu; Adewumi Adediran; Olajumoke Oshinaike; Phillip Adebola; Olanrewaju Arogundade
Journal:  BMC Res Notes       Date:  2012-08-01

5.  Extracellular fluid tonicity impacts sickle red blood cell deformability and adhesion.

Authors:  Marcus A Carden; Meredith E Fay; Xinran Lu; Robert G Mannino; Yumiko Sakurai; Jordan C Ciciliano; Caroline E Hansen; Satheesh Chonat; Clinton H Joiner; David K Wood; Wilbur A Lam
Journal:  Blood       Date:  2017-10-04       Impact factor: 25.476

6.  CD4+ T Lymphocytes count in sickle cell anaemia patients attending a tertiary hospital.

Authors:  Omotola Toyin Ojo; Wuraola Adebola Shokunbi
Journal:  Niger Med J       Date:  2014-05

7.  Fluid overload due to intravenous fluid therapy for vaso-occlusive crisis in sickle cell disease: incidence and risk factors.

Authors:  Aafke E Gaartman; Ajab K Sayedi; Jorn J Gerritsma; Tim R de Back; Charlotte F van Tuijn; Man Wai Tang; Harriët Heijboer; Koen de Heer; Bart J Biemond; Erfan Nur
Journal:  Br J Haematol       Date:  2021-07-15       Impact factor: 6.998

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.